Web Exclusives

Value-Based Paradigms in Multiple Myeloma: Pharmacoeconomic Analysis of Novel Therapies
Over the past 2 decades, the standard of care for multiple myeloma (MM) has shifted with the introduction of novel, targeted agents such as bortezomib, lenalidomide, and thalidomide.
Read More

Assessing the Value of Complete Response in Patients with Multiple Myeloma
The treatment of multiple myeloma (MM) is advancing to the point where it is becoming a chronic disease.
Read More

Treating Newly Diagnosed Multiple Myeloma: Data on Safety, Efficacy, and Dosing Regimens
he therapeutic paradigm for multiple myeloma (MM) continues to evolve, due to advances in our understanding of the molecular and genetic basis of the disease.
Read More

What Is the Best Strategy for Managing Myeloma-Related Bone Disease?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.
Read More

How Can Symptom Management Be Optimized to Improve Quality of Life?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.
Read More

Will Maintenance Therapy Provide a Real Benefit?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

How Should Progression-Free Survival Data Be Interpreted?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

How Should a Newly Diagnosed, Nontransplant Patient Be Managed?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

Which Imaging Techniques Should Be Used at Diagnosis and to Monitor Treatment Efficacy?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

Is There an Optimal Induction Therapy for Transplant-Eligible Patients?
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
Read More

Page 3 of 4

Subscribe to
Value-Based Care in Neurology

Stay up to date with personalized medicine by subscribing to recieve the free VBCN e‑Newsletter.

I'd like to recieve: